{"id":69485,"date":"2026-07-07T14:13:14","date_gmt":"2026-07-07T06:13:14","guid":{"rendered":"https:\/\/flcube.com\/?p=69485"},"modified":"2026-07-07T14:13:16","modified_gmt":"2026-07-07T06:13:16","slug":"carephar-pharmaceutical-silk-road-medical-forge-central-asia-deal-for-keverprazan-p-cab-innovation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69485","title":{"rendered":"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Carephar Pharmaceutical Co., Ltd.<\/strong> and <strong>Silk Road Medical Technology<\/strong> announced a <strong>strategic cooperation agreement<\/strong> in Almaty, establishing an <strong>exclusive sales licensing arrangement<\/strong> for Carephar&#8217;s <strong>Keverprazan Hydrochloride Tablets<\/strong> across three Central Asian markets: <strong>Kazakhstan<\/strong>, <strong>Uzbekistan<\/strong>, and <strong>Kyrgyzstan<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-market-access\" class=\"wp-block-heading\">Deal Structure &amp; Market Access<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Exclusive sales licensing agreement<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Kazakhstan, Uzbekistan, Kyrgyzstan (Central Asia)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Keverprazan Hydrochloride Tablets (Class 1 innovative drug)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Potassium-competitive acid blocker (P-CAB)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First Chinese-developed P-CAB to enter Central Asian markets<\/td><\/tr><tr><td><strong>Announcement Location<\/strong><\/td><td>Almaty, Kazakhstan (Silk Road Medical headquarters)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-competitive-positioning\" class=\"wp-block-heading\">Product Profile &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Status:<\/strong> <strong>Class 1 innovative drug<\/strong> developed by Carephar; <strong>first P-CAB independently developed by a Chinese enterprise<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Milestone:<\/strong> Listed in China&#8217;s <strong>National Reimbursement Drug List (NRDL)<\/strong> in 2024, ensuring broad patient access<\/li>\n\n\n\n<li><strong>Current Market Penetration:<\/strong> Available in <strong>over 2,000 hospitals nationwide<\/strong> across China<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> P-CABs offer faster onset of action, more consistent acid suppression, and improved efficacy compared to traditional proton pump inhibitors (PPIs)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-rationale\" class=\"wp-block-heading\">Strategic Partnership Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Strategic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Carephar Pharmaceutical<\/strong><\/td><td>Expands international footprint without establishing local commercial infrastructure; leverages Silk Road Medical&#8217;s established distribution network across Central Asia<\/td><\/tr><tr><td><strong>Silk Road Medical<\/strong><\/td><td>Diversifies pharmaceutical portfolio with premium innovative product; strengthens position as preferred partner for Chinese pharmaceutical companies entering Central Asian markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Silk Road Medical Technology, headquartered in Almaty, maintains comprehensive capabilities in the supply and service of experimental reagents, medical equipment, medical consumables, chemical and biological pharmaceuticals, and vaccines, providing an integrated platform for Carephar&#8217;s market entry.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-regional-context\" class=\"wp-block-heading\">Market Opportunity &amp; Regional Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Central Asian Pharmaceutical Market:<\/strong> Combined market valued at approximately $3.2 billion in 2025, growing at 8.5% CAGR driven by aging populations and increasing healthcare expenditure<\/li>\n\n\n\n<li><strong>Acid-Related Disorders Prevalence:<\/strong> High incidence of gastroesophageal reflux disease (GERD) and peptic ulcers across Central Asia, with limited access to next-generation acid suppressants<\/li>\n\n\n\n<li><strong>Chinese Pharmaceutical Expansion:<\/strong> Part of broader trend of Chinese innovative drugs gaining international recognition, with Central Asia representing a strategic gateway to broader Eurasian markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the Carephar-Silk Road Medical partnership, including market expansion plans, commercial expectations, and regulatory developments. Actual results may differ due to risks including local regulatory approvals, market adoption rates, competitive dynamics, and geopolitical factors affecting Central Asian markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69486,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[3202,4836],"class_list":["post-69485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-carephar-pharmaceutical","tag-silk-road-medical-technology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement in Almaty, establishing an exclusive sales licensing arrangement for Carephar&#039;s Keverprazan Hydrochloride Tablets across three Central Asian markets: Kazakhstan, Uzbekistan, and Kyrgyzstan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69485\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement in Almaty, establishing an exclusive sales licensing arrangement for Carephar&#039;s Keverprazan Hydrochloride Tablets across three Central Asian markets: Kazakhstan, Uzbekistan, and Kyrgyzstan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69485\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T06:13:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T06:13:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation\",\"datePublished\":\"2026-07-07T06:13:14+00:00\",\"dateModified\":\"2026-07-07T06:13:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485\"},\"wordCount\":392,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0701.webp\",\"keywords\":[\"Carephar Pharmaceutical\",\"Silk Road Medical Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69485#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69485\",\"name\":\"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0701.webp\",\"datePublished\":\"2026-07-07T06:13:14+00:00\",\"dateModified\":\"2026-07-07T06:13:16+00:00\",\"description\":\"Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement in Almaty, establishing an exclusive sales licensing arrangement for Carephar's Keverprazan Hydrochloride Tablets across three Central Asian markets: Kazakhstan, Uzbekistan, and Kyrgyzstan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69485\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69485#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement in Almaty, establishing an exclusive sales licensing arrangement for Carephar's Keverprazan Hydrochloride Tablets across three Central Asian markets: Kazakhstan, Uzbekistan, and Kyrgyzstan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69485","og_locale":"en_US","og_type":"article","og_title":"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation","og_description":"Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement in Almaty, establishing an exclusive sales licensing arrangement for Carephar's Keverprazan Hydrochloride Tablets across three Central Asian markets: Kazakhstan, Uzbekistan, and Kyrgyzstan.","og_url":"https:\/\/flcube.com\/?p=69485","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T06:13:14+00:00","article_modified_time":"2026-07-07T06:13:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69485#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69485"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation","datePublished":"2026-07-07T06:13:14+00:00","dateModified":"2026-07-07T06:13:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69485"},"wordCount":392,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69485#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0701.webp","keywords":["Carephar Pharmaceutical","Silk Road Medical Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69485#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69485","url":"https:\/\/flcube.com\/?p=69485","name":"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69485#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69485#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0701.webp","datePublished":"2026-07-07T06:13:14+00:00","dateModified":"2026-07-07T06:13:16+00:00","description":"Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement in Almaty, establishing an exclusive sales licensing arrangement for Carephar's Keverprazan Hydrochloride Tablets across three Central Asian markets: Kazakhstan, Uzbekistan, and Kyrgyzstan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69485#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69485"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69485#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0701.webp","width":1080,"height":608,"caption":"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69485#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69485"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69485\/revisions"}],"predecessor-version":[{"id":69487,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69485\/revisions\/69487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69486"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}